Noven Pharmaceuticals, Inc.

Dow Corning Corporation

Dow Corning France Sas

David P Kanios

Juan A Mantelle

David Houze

Viet Nguyen

Rod L Hartwig

Linda Sue Nartker

Chensheng Li

Paul Johnson

Steven Sablotsky

Timothy Paul Mitchell

Katherine L Ulman

Xavier Jean-Paul Thomas

Victor Albert Raul

Chana Wilson Evans

Robert O Huber

Gary Lee Loubert

Joseph A Gentile

Tiffany Anne Menjoulet

Terese A Dixon

Sylvia Rossi-Montero

David W Houze

A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.

Transdermal drug delivery device including an occlusive backing

A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.

Device for transdermal administration of drugs including acrylic based polymers

Device for transdermal administration of drugs including acrylic polymers

A blend of at least two polymers in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin.

Compositions and methods for delivering active agents in transdermal drug delivery systems

Described are flexible, finite systems for the transdermal administration of scopolamine, comprising: (a) a polymer matrix comprising a polymer blend comprising (i) a non-functional acrylic-based polymer constituting at least about 60% by weight of the dry weight of the polymer matrix, and (ii) an amine-resistant capped silicone polymer constituting not more than about 30% by weight of the dry weight of the polymer matrix; and (b) scopolamine solubilized in the polymer matrix, wherein the flexible, finite system is substantially free of vinyl acetate and polar components. In some embodiments, the polymer matrix also comprises a non-polar penetration enhancer. Methods of making and using such flexible, finite systems also are described.

Compositions and methods for delivery of amino-functional drugs

A transdermal delivery system is provided for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric and/or adhesive coating that is applied to either the transdermal system's backing or release liner. The transdermal delivery device is manufactured to optimize drug loading while providing desirable adhesion to skin or mucosa as well as providing modulation of the drug delivery and profile.

Compositions and methods for controlling drug loss and delivery in transdermal drug delivery systems

Compositions and methods for the continuous and controlled transdermal delivery of an active agent from a pharmaceutically acceptable carrier composition comprising a polyoxazoline polymer, wherein the active drug incorporated in the carrier composition of the transdermal system remains substantially solubilized and stable during storage prior to use.

Inhibiting crystallization of steroidal hormones in transdermal delivery systems

This invention provides a single phase silicone acrylate formulation that resists phase separation and includes (A) at least one of a silicone, an acrylate, and combinations thereof. The single phase silicone acrylate formulation also includes (B) a silicone acrylate hybrid compatibilizing agent including silicone functionality and (meth)acrylate functionality and that is the reaction product of a silicon-containing pressure sensitive adhesive composition, a (meth)acrylate, and an initiator. A method of minimizing phase separation of the single phase silicone acrylate formulation includes the step of combining (A) and (B) to form the single phase silicone acrylate formulation.

Single phase silicone acrylate formulation

Compositions and methods for controlling the flux of a drug from a transdermal drug delivery systems

Growing community of inventors

Miami, FL, United States of America

David P Kanios